Abstract:

Endometrial cancer, cervical cancer and ovarian cancer are the three most common gynecological malignancies. The treatment methods are mainly surgery, radiotherapy and chemotherapy. However, the recurrence rate and metastasis rate are still high. By blocking the binding of inhibitory checkpoints and their ligands, immune checkpoint inhibitors activate the activity of immune cells and achieve antitumor effects. With the deepening of the research on immune checkpoint inhibitors in gynecological tumors, it is found that the objective response rate is mostly about 10%-20%, and the combination of radiotherapy and chemotherapy can greatly improve the curative effect, which may provide greater clinical benefits for gynecological tumor patients. However, its adverse reactions can not be ignored, such as skin itching, mucositis, diarrhea and colitis. Therefore, exploring predictive biomarkers, screening the applicable population for immune checkpoint inhibitor treatment, early identification and reasonable intervention of adverse events are very important for the application of immune checkpoint inhibitors in gynecological malignant tumors.

Key words: Programmed cell death receptor 1, CTLA-4 antigen, Genital neoplasms, female, Immunotherapy, Immune checkpoint inhibitor